Sun Pharma Set For Bumpy Drive To Reach Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
Analysts are growing cautious on the mega Sun-Ranbaxy deal, raising doubts on the timelines for regulatory approvals and the fallout of court proceedings. Some have questioned if an open bidding process could have been followed to win a higher value for Ranbaxy shareholders.